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Abstract. The differential diagnosis among various 
types of non-functioning sellar and parasellar tumours is 
sometimes difficult using currently available methods of 
morphological imaging. The aim of this study was to de- 
fine whether assessment of the uptake of [18F]fluoro-eth- 
yl-spiperone (FESP) with positron emission tomography 
(PET) could be helpful for the differential diagnosis of 
pituitary adenomas and other parasellar lesions, and for 
establishing the appropriate therapeutic approach. The 
population examined comprised 16 patients with the di- 
agnosis of primary tumour of the sellar/parasellar region 
who were waiting to undergo surgical treatment. The re- 
sults demonstrated that PET with [18F]FESP is a very 
specific method for differentiating adenomas from cra- 
niopharyngiomas nd meningiomas. The visual interpre- 
tation of images allows such differentiation at approxi- 
mately 70 rain after tracer injection. Semiquantitative 
analysis of the dynamic PET data confirmed the results 
of visual interpretation, demonstrating that the uptake of 
[18F]FESP was consistently (i.e. throughout the series) at 
least two- to threefold higher in non-functioning adeno- 
mas than in other parasellar tumours as early as 70 min 
after tracer injection, and that it increased still further 
thereafter. It is concluded that PET with [laF]FESP 
might be of clinical value in those cases in which the 
differential diagnosis among various histological types 
of sellar tumour is uncertain with conventional methods. 
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I n t roduct ion  
The most common sellar and parasellar tumours are, in 
order of frequency, pituitary adenomas, meningiomas, 
craniopharyngiomas, neurinomas and cordomas. The 
differential diagnosis of these tumours is currently based 
on clinical, radiological and endocrine features. The di- 
agnosis of secreting pituitary adenoma is usually obvi- 
ous because of signs and symptoms characteristic ofhor- 
mone hypersecretion [1]. Non-functioning pituitary ade- 
nomas, as well as meningiomas and craniopharyngio- 
mas, do not cause any specific endocrine syndrome; thus 
their presence is usually suggested by the evidence of 
compression of the parasellar nervous structures. In this 
case, the differential diagnosis among the various types 
of non-functioning tumours that invade the parasellar re- 
gion is of the utmost importance because the selection of 
the appropriate surgical approach may vary depending 
on the nature of the tumour. The differential diagnosis in 
these cases is usually achieved by neuroradiological 
studies, especially by means of magnetic resonance im- 
aging (MRI), a technique that has greatly improved the 
delineation of pituitary masses. Radiological differential 
diagnosis, nevertheless, occasionally may be difficult or 
even impossible using currently available laboratory and 
imaging tools, in particular in cases of primary parasel- 
lar lesions with presentation i the sellar region. At our 
department diagnostic uncertainty after MRI investiga- 
tion occurs in about 10% of patients with hormonally in- 
active tumours of the sellar region. In such selected 
cases, the in vivo characterization of the biochemical 
and functional properties of the tissue, by positron emis- 
sion tomography (PET) and single-photon emission to- 
mography (SPET), may provide useful information 
about he nature of the pituitary mass [2]. 
PET has previously been used for the assessment of
pituitary adenomas and other parasellar tumours with 
several tracers, including [llC]methionine, [llC]tyrosine, 
[lSF]fluorodeoxyglucose, [UC]deprenyl, [llC]_N_meth- 
ylspiperone and [llC]raclopride [3-7]. 
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Some of  the methods proposed for the assessment of 
sellar and parasel lar tumours are based on the measure- 
ment of b iochemical  processes that are not specific to 
any particular type of neoplastic tissue, i.e. the rate of 
glucose metabol ism and protein synthesis. These vari- 
ables may indicate a neoplastic process when they are 
abnormal ly increased or decreased [8]. Such methods 
have been shown to be useful for visual iz ing pituitary 
adenomas, for differentiating between viable neoplastic 
tissue and scar, and for assessing the response to phar- 
macological  treatment [9]. 
Other methods are based instead on the use of radio- 
pharmaceuticals that trace processes that take place in 
the normal and abnormal pituitary tissue, but neither in 
the other tumours of the sella nor in the nearest sur- 
rounding tissue. To this end, the use of  [l~C]deprenyl, a 
tracer that irreversibly binds to monoamino oxidase B 
(MAO-B),  has been val idated for the differential diagno- 
sis of pituitary adenomas and meningiomas [10]. 
There is another feature, i.e. the expression of D 2 do- 
pamine receptors, that may be useful for the differential 
diagnosis of pituitary adenomas from meningiomas and 
other parasel lar tumours. However, whereas both [ l lC]- 
N-methylspiperone and [11C]raclopride [ 11 ], two antag- 
onists of the D 2 dopamine receptors, have been used to 
visual ize pituitary adenomas, the assessment of the bind- 
ing of PET tracers to D 2 dopamine receptors has not 
been systematical ly tested and exploited for differentiat- 
ing pituitary adenomas from other types of parasel lar tu- 
mours. 
This study was aimed at evaluating the possibi l i ty of 
using PET and [18F]fluoro-ethyl-spiperone (FESP), a 
tracer with high affinity for D 2 dopamine receptors, for 
the differential diagnosis of adenomas and other tumours 
of the sellar and parasel lar egion, based on the expres- 
sion of D 2 dopamine receptors by pituitary adenomas, in 
a group of consecutive patients wait ing to undergo surgi- 
cal treatment. 
Materials and methods 
In vivo PET studies 
Patients. The population examined comprised 16 patients (eight 
males and eight females; mean age 49 years; range: 16-73 years) 
with the diagnosis of primary tumour of the sellar/parasellar re-
gion who were waiting to undergo surgical treatment. The main 
clinical features of the study population are summarized in Table 
1. Endocrine valuation included measurement of basal evels of 
FT 3, FT 4, testosterone or 17-[3-oestradiol, as appropriate, and free 
urinary cortisol. Moreover, in all patients the response of PRL, 
TSH, LH and FSH to the i.v. administration f 200 gg TRH was 
assessed. Preoperative neuroradiological assessment included in 
all cases a skull X-ray and an MRI study of the sella. Based on ra- 
diological, clinical and endocrine features, seven patients had a 
presurgical diagnosis of non-functioning pituitary adenoma, three 
of meningioma, nd three of craniopharyngioma; in the remaining 
three subjects the presurgical diagnosis was uncertain (see case re- 
ports). All subjects underwent a PET study with [IaF]FESP). The 
PET study was approved by the Ethical Committee of the San Ra- 
ffaele Hospital. Participation i the study was voluntary and writ- 
ten informed consent was obtained from each subject. 
Radiochemistry. No-carrier-added aqueous [18F]fluoride was pro- 
duced with an 180(p,n)laF nuclear eaction by proton bombard- 
ment of an 180-enriched water target, with a CTI/Siemens RDS 
112 cyclotron (Siemens/CPS, Knoxville, Tenn., USA). The syn- 
thesis of [laF]FESP was carried out according to the method of 
Satyamurthy etal. [12] with minor modifications of the HPLC pu- 
rification procedure (ammonium acetate 0.025 M pH 4.8/CH3CN, 
Table 1. Clinical data in 16 patients operated on for a lesion of the sellar egion 
Patient Age, Pituitary Diabetes Visual Maximal Type of PET Immuno- 
no. gender function insipidus defects tumour operation histo- 
diameter chemistry 
(ram) 
Pathology 
1 67, M G No No 27 TNS + FSH + (60%) 
2 28, F G No Yes 35 TC + PRL + (5%) 
3 70, M Normal No Yes 31 TNS + Negative 
4 40, F G No No 21 TNS + Negative 
5 48, F G No Yes 54 TC + Negative 
6 56, M G No Yes 42 TNS + Negative 
7 59, M Normal No Yes 38 TNS + Negative 
8 73, M Normal No Yes 43 TNS + Negative 
9 63, F G No Yes 42 TC - ND 
10 42, F G No No 38 TC - ND 
11 57, F Normal No Yes 29 TC - ND 
12 60, M G No No 24 TNS - ND 
13 44, F G No Yes 55 TC - ND 
14 37, M G, T Yes Yes 41 TC - ND 
15 63, F G, T, A Yes Yes 37 TC - ND 
16 16, F G No Yes 36 TNS - ND 
Adenoma 
Adenoma 
Adenoma 
Adenoma 
Adenoma 
Adenoma 
Adenoma 
Adenoma 
Meningioma 
Meningioma 
Meningioma 
Meningioma 
Craniopharyngioma 
Craniopharyngioma 
Craniopharyngioma 
Craniopharyngioma 
G, Hypogonadism; T, hypothyroidism; A, hypoadrenalism; TNS, trans-sphenoidal; TC, transcra~aial; ND, not determined 
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40/60 vol/vol; viosil C18 10-gin column; flow rate 10 ml/min). 
The resulting product was dissolved in a solution of saline con- 
taining 5% ethanol and passed through a Gelman acrodisc sterile 
filter into a sterile vial. The radiochemical purity of the tracer pro- 
duced was higher than 96%. The specific activity, determined by 
HPLC analysis using a U.V. detector, ranged between 5 and 
10 Ci/~tmole. The sterility and presence of pyrogen, was tested for 
each preparation by bacteriological nalysis and by the limutus 
amebocyte lysate test. 
PET studies. [lSF]FESP PET studies were performed with either a 
four-ring (ECAT-931/04-12; Siemens/CPS, Knoxville, Tenn., 
USA) or an 18-ring (GE-Advance; General Electric Medical 
System, Milwaukee, Wis., USA) whole-body positron emission 
tomograph. Patients were positioned on the scanner bed with their 
heads immobilized in the scanner head holder. In order to centre 
the lesion inside the field of view of the tomograph, positioning of 
the patient's head was achieved with the aid of laser beams and on 
the basis of MRI and computed tomography (CT) images. One 
15-min transmission scan was carried out with an external germa- 
nium-68 ring source. At the end of the transmission scan, patients 
received an intravenous injection of 120 pCi/kg of [lSF]FESE Af- 
ter tracer injection, sequential scans were acquired. Simultaneous 
acquisition of data from seven transaxial planes (four direct and 
three cross planes; slice thickness 6.75 ram) parallel to the orbito- 
meatal line and covering an axial field of view of 5.4 cm was car- 
ried out with the ECAT tomograph. Data from 35 transaxial 
planes (18 direct and 17 cross planes; slice thickness 4.25 mm) 
parallel to the orbitomeatal line and covering an axial field of 
view of 15.2 cm were collected with the GE-Advance-tomograph. 
Scanning proceeded according to the following schedule: five 
scans of 1 min each followed by five scans of 2 rain each and 21 
scans of 5 min each. The total scanning time after tracer injection 
was 70 rain in all 16 patients. Patient compliance allowed us to 
prolong the study to 90 rain in 12/16 subjects, and to 120 min in 
9/16 subjects. Image reconstruction was performed using a 
filtered back-projection algorithm with an Hann filter (cut-off 
frequency 0.5 cycles/pixel) for the ECAT machine, while for the 
GE-Advance a Hanning filter (cut-off frequency 6.4 mm) was 
used; under these conditions the spatial resolution in the image 
plane was -8.5 mm full-width at half-maximum; images were 
reconstructed on a 128xl28 matrix with a pixel size of 1.6 ram. 
Correction for attenuation f the 51 l-keV y-rays by the tissue was 
performed with the coefficients obtained from the measured 
trasmission scan. 
Histological studies. All patients underwent surgical treatment 
and histological examination of the tissue specimens obtained at 
the time of surgery. For light microscopy, specimens of tumour 
tissue were fixed in 10% buffered formalin and embedded in par- 
affin. Sections of 4-6 gm thickness were stained with haematoxy- 
lin-eosin and the PAS technique. Immunohistochemistry was per- 
formed in pituitary adenomas, using the avidin-biotin-peroxidase 
complex method, Paraffin sections of 4-6 gm thickness were im- 
munostained for GH, PRL, TSH, ACTH, LH and FSH with com- 
mercially available specific rabbit antisera. 
Data analysis. Reconstructed images were transferred to a SUN 
(SPARC) workstation for image processing. 
Visual interpretation f PET images was carried out by three 
physicians unaware of the type of tumour affecting each patient. 
Each physician was required to visually interpret the sequence of 
timed PET images of each patient and to score each study as ei- 
ther positive or negative for the presence of abnormal tracer up- 
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take in the pituitary and surrounding tissue at the time of the last 
scanning. After the initial evaluation, consensus was achieved by 
collegial examination. 
For semiquantitative analysis the cerebellum, an area substan- 
tially devoid of D 2 dopamine receptors, was chosen as the refer- 
ence area to estimate the ratio of tumour-to-brain (T/Cb) binding 
of [18F]FESP to D 2 receptors. Measurement of [18F]FESP uptake 
was carried out on PET brain images in the region of the tumour 
and in the cerebellar tissue. Based on either MRI or X-ray CT, ir- 
regular egions of interest (ROIs) encompassing the lesion and the 
cerebellar tissue were drawn on the PET images of the final emis- 
sion scan. Images from the final emission scan were then trans- 
ferred to the images from each of the other emission scans to ob- 
tain the time course of total radioactivity in each ROI. Data were 
corrected for the physical decay of the 18F from the time of the in- 
jection to the midpoint of the imaging scans. 
The ratios of tumour activity to that of cerebeltar tissue (T/Cb) 
after tracer injection were calculated at discrete time points from 
the time of injection up to the end of the study. 
Results 
Pathology 
Histological assay on tumour specimens obtained by 
surgery confirmed the preoperative diagnosis in the 13 
patients in whom the diagnosis had been made before 
surgery: seven were pituitary adenomas, three were men- 
ingiomas and three were craniopharyngiomas. Of the 
three undiagnosed lesions, one was a pituitary adenoma, 
one was a meningioma nd one was a craniopharyngio- 
ma (see case reports). 
PET results 
Visual interpretation. An area of increased ~8F uptake, 
corresponding to the MR images of the lesions, was de- 
tectable on the PET images obtained in eight subjects. 
When the results were examined in relation to the pa- 
thology examination, the tracer uptake was confirmed in 
the patients with adenoma, whereas no tracer uptake was 
visible in any of the other tumours. 
Semiquantitative analysis. The average time course of 
the turnout-to-brain radioactivity concentration ratio 
(T/Cb ratio) in the 16 patients examined, is shown in 
Fig. 1. A progressive increase in the T/Cb ratios over 
time was noted only in the pituitm'y adenomas, with val- 
ues between 4 and 8 being reached at 120 min after trac- 
er injection. T/Cb ratios were less than 2 for all patients 
with parasellar tumours other than adenomas at all times 
after tracer injection (Fig. 2). 
Case reports" 
Patient no. 8. A 73-year-old man presented at the emer- 
gency department of our hospital complaining of sudden 
onset of headache and severe visual defect in both eyes. 
The patient reported that 3 years earlier a cerebral CT 
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Fig. 1. Time course of the tumour/cerebellum activity ratios of 
[IaF]FESP in 16 patients with sellar tumours. Solid circles, pitui- 
tary adenomas; open triangles, meningiomas nd craniopharyngi- 
omas 
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Fig. 2. Tumour/cerebellum activity ratios of [ISF]FESP in 16 pa- 
tients with sellar tumours, 70 rain after i.v. administration f trac- 
er. RA., Pituitary adenoma; CR, craniopharyngioma; MEN, men- 
ingioma 
scan, performed because of chronic headache, showed 
the presence of an intrasellar and slightly suprasellar le- 
sion of the pituitary fossa, compatible with a pituitary 
adenoma. A neurosurgical consultant did not advise sur- 
gical therapy of the lesion, mainly because of the lack of 
serious symptoms, but recommended neuroradiological 
examinations at regular intervals. The patient, however, 
failed to present at follow-up visits. In the ensuing 3 
years the patient experienced increasing headache and 
bilateral worsening of visual acuity. An emergency MRI 
demonstrated the presence of a huge suprasellar lesion, 
extending anteriorly toward the frontal lobes, whereas 
the sella turcica appeared minimally involved. Small ar- 
eas of hyperintense signal on Tl-weighted images were 
consistent with intratumoural haemorrhage and the 
abrupt deterioration of vision. Endocrine evaluation did 
not reveal any hormonal hypersecretion. The MRI pic- 
ture was more suggestive of a primary suprasellar lesion, 
possibly a meningioma, but the clinical history was more 
suggestive of apoplexy of a non-functioning adenoma. 
The PET study revealed an area of marked uptake of 
tracer corresponding to the lesion shown by MRI 
(Fig. 3). A biopsy was performed via the transsphenoidal 
Fig. 3. MRI coronal image (A) and PET transaxial images (B) of 
the brain in a patient with pituitary adenoma (see case report for 
patient no. 8). Marked focal tracer uptake is observed on the PET 
image in an area consistent with the area of lesion observed on 
MRI 
approach: after opening the dura a partially necrotic pi- 
tuitary adenoma was found and an estimated 50% of the 
mass was removed. The presence of a non-functioning 
pituitary adenoma that did not stain for any pituitary 
hormone was shown by histology. Postoperatively the 
patient recovered uneventfully. Slight amelioration of vi- 
sion was reported uring the first days after surgery. Two 
months after surgery the patient partially regained his vi- 
sual acuity in both eyes. A repeat MRI 4 months after 
surgery showed residual adenomatous tissue, but a clear 
decrease in compression of the surrounding nervous 
structures. Further treatment of the residual adenoma has 
still to be planned. 
Patient no. 12. A 60-year-old man presented at the emer- 
gency department of another hospital because of the sud- 
den onset of diplopia. Neurological examination dis- 
closed palsy of the VIth left cranial nerve. ACT scan re- 
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vealed a lesion located in the left cavernous inus that 
extended ownward into the sphenoid sinus. The patient 
was then referred to the neurosurgical department of our 
hospital. Endocrine valuation did not reveal any signifi- 
cant abnormality. The differential diagnosis was restrict- 
ed between a meningioma of the cavernous sinus and a 
pituitary adenoma, especially in the light of the involve- 
ment of the sphenoid sinus. MRI of the sellar region 
confirmed the presence of a mass growing mainly within 
the left cavernous sinus and extending into the sphenoid 
sinus. The PET study did not reveal any tracer uptake in 
the area corresponding to the lesion shown by MRI. The 
patient was operated on via the trans-sphenoidal ap- 
proach to obtain a biopsy specimen of the lesion grow- 
ing in the sphenoid sinus. At operation, firm tissue was 
detected and biopsied in the sphenoid sinus; the gross 
appearance of the lesion was suggestive of a meningio- 
ma, which was confirmed by pathological examination 
of the removed tissue. The patient recovered uneventful- 
ly. Three months after operation, radiosurgery was per- 
formed and the patient experienced a slow resolution of 
diplopia. At the last follow-up, 12 months after radiosur- 
gery, the patient was well and a repeat MRI showed a 
small decrease in the size of the residual lesion within 
the cavernous sinus. 
Patient no. 16. A 16-year-old girl was referred to our 
hospital because of bilateral temporal hemianopia nd 
visual impairment in the left eye. The girl also had pri- 
mary amenorrhoea, but no diabetes insipidus. Endocrine 
evaluation revealed an impaired functional reserve of the 
pituitary. MRI disclosed an intrasellar lesion that extend- 
ed upward into the suprasellar spaces to compress the 
optic chiasm and, particularly, the left optic nerve. The 
lesion, which appeared hypointense on Tl-weighted im- 
ages, showed a strong signal enhancement after the i.v. 
administration f paramagnetic contrast only in the pe- 
ripheral part of the mass. No calcifications were visible 
on skull X-ray and CT scan. The neuroradiological pic- 
ture was suggestive of a craniopharyngioma or of a cys- 
tic pituitary adenoma. The PET study did not reveal any 
tracer uptake in the area of the lesion shown by MRI. 
The patient was operated on via the trans-sphenoidal ap- 
proach. After opening the dura a typical craniopharyngi- 
oma appeared and was entirely removed, except for a 
rim of tissue in the suprasellar space that was firmly ad- 
herent o the dura. Histology confirmed that the lesion 
was a craniopharyngioma. The patient recovered un- 
eventfully after surgery and treatment with L-thyroxine, 
hydrocortisone acetate and oestrogen substitution thera- 
py was commenced because of persisting hypopituitar- 
ism. Recovery of vision in the left eye and marked im- 
provement of visual fields occurred within 2 months. 
Postoperative MRI demonstrated the presence of intra- 
sellar pathological tissue that was treated by radiosur- 
gery 6 months after operation. 
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Discussion 
Differential diagnosis of sellar and parasellar lesions 
may be of paramount importance when deciding the 
therapeutic approach to the patient. The most common 
problem concerns the differentiation between on-func- 
tioning pituitary adenomas, craniopharyngiomas and su- 
prasellar meningiomas. The clinical picture of these tu- 
mours is aspecific, with the sole exception of diabetes 
insipidus, which is typical of craniopharyngioma and al- 
most always absent in pituitary adenoma. MRI of the 
sella has greatly improved the preoperative differentia- 
tion of sellar lesions, because of better delineation of an- 
atomical details and differences in signal intensity. Nev- 
ertheless, in a few patients a straightforward distinction 
among the various tumour types is not feasible ven af- 
ter a thorough MRI study. 
Functional characteristics of the sellar lesions, such 
as metabolism and presence of specific types of cellular 
receptors, can now be investigated in vivo by PET and 
SPET techniques. Based on the premise that tumours of 
different origin should possess pecific functional char- 
acteristics, it was hoped that PET and SPET studies 
could lead to a clear-cut diagnosis of sellar lesions of un- 
certain origin. However, so far the results of such studies 
have in most cases been disappointing. PET with 
[llC]methionine can separate pituitary adenoma from 
neurinoma [6], but, in our experience, neurinomas can 
mimic a pituitary adenoma very rarely. The presence of 
octreotide-binding somatostatin receptors on pituitary 
tumours allows their in vivo detection after the injection 
of radionuclide-labelled octreotide. Most of non-func- 
tioning adenomas were visualized by 111In-DTPA-oct- 
reotide in one study [13], but not in another based on the 
use of 123I-Tyr3-octreotide [14]. Moreover, meningiomas 
also may express omatostatin receptors and can be visu- 
alized by somatostatin receptor scintigraphy [15], ren- 
dering this method of limited usefulness in the differen- 
tial diagnosis of sellar lesions. 
Promising results were obtained when the content of 
the enzyme MAO-B was investigated in pituitary adeno- 
mas and meningiomas. [11C]Deprenyl, a drug that irre- 
versibly binds to MAO-B, was shown to accumulate in
adenomas but not in meningiomas [10]. However, ahigh 
degree of heterogeneity in the MAO-B concentrations 
was present among the adenomas examined, causing low 
tumour-to-brain radioactivity ratios in some adenomas, 
and thus hampering the interpretation f low [llC]dep- 
renyl uptake. Our data are consistent with those of Pirker 
et al., who showed specific binding of 12~I-labelled p- 
idepride in a small series of non-functioning pituitary 
adenomas [16]. 
Dopamine D 2 receptor agonists are used in the treat- 
ment of pituitary adenomas. Several tracers bind to the 
D 2 receptors and can be used to visualize such receptors 
in vivo by emission tomography, but their use has not 
yet been investigated asa diagnostic tool to differentiate 
non-functioning pituitary adenomas from other sellar le- 
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sions, probably because the former are generally consid- 
ered deficient in dopamine receptors. In fact, chronic 
treatment with dopaminergic drugs, such as bromocrip- 
tine and quinagolide, is usually ineffective in patients 
with non-functioning adenomas [17, 18], in clear con- 
trast to the high response rate observed in patients with 
PRL-secreting adenomas [19-21]. In vitro studies clear- 
ly demonstrated the presence of high-affinity dopamine 
receptors in non-functioning pituitary adenomas, al- 
though the number of binding sites was lower than in 
PRL-secreting adenomas and normal pituitary [17, 22]; 
it must also be noted that a clear role for the D 2 recep- 
tors in non-functioning adenomas has not yet been de- 
fined. Since meningiomas and craniopharyngiomas re 
not known to possess D 2 dopamine receptors, in vivo vi- 
sualization of the D 2 receptor in a pituitary lesion of un- 
certain origin could permit the differential diagnosis of a 
non-functioning pituitary adenoma from other non-ade- 
nomatous lesions. Our study demonstrates that PET with 
[18F]FESP is a very specific method for the achievement 
of this aim. All the eight non-functioning adenomas in- 
vestigated showed uptake of [18F]FESP that was signifi- 
cantly higher than in the patients with parasellar menin- 
giomas or craniopharyngiomas, without overlap among 
the different groups. The visual interpretation of images 
allowed such differentiation at times as early as 70 min 
after tracer injection. The semiquantitative analysis of 
the dynamic data confirmed the results of visual inter- 
pretation and demonstrated that the uptake of [18F]FESP 
was at least two- to threefold higher in non-functioning 
adenomas than in other parasellar tumours as early as 
70 rain after tracer injection, and increased still further 
thereafter, in contrast o the time course of activity in the 
other parasellar tumours. 
Patients in our study were not selected on the basis of 
uncertainty of the preoperative diagnosis. In fact, 13 of 
the study patients had a clinical and neuroradiological 
picture suggestive of non-functioning adenoma (seven 
patients), meningioma (three patients) or craniopharyn- 
gioma (three patients), whereas only three patients pre- 
sented with an equivocal preoperative diagnosis. Thus, a 
larger population with uncertain diagnoses needs to be 
examined in a prospective study, in which the advanta- 
ges of the information obtained with [18F]FESP PET 
with regard to patient management and surgical ap- 
proach can be addressed. Nevertheless, our results prove 
the rationale and provide the basis for the use [laF]FESP 
PET to differentiate non-functioning pituitary adenomas 
from other lesions of the sellar region, such as meningio- 
mas and craniopharyngiomas, thus allowing a more ra- 
tional therapeutic approach when the MR! findings are 
not diagnostic. 
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